Author Archives: Forest Ray PhD

Board Recommends All Anavex 2-73 Trials Proceed

An independent monitoring board has recommended that all three ongoing clinical trials of Anavex 2-73 (blarcamesine), an investigational treatment for Rett syndrome, continue without changes, based on a review of interim safety data. Anavex Life Sciences, the medication’s developer, announced the decision in a press release. Data…

COVID-19 Vaccine Compatible with Trial Testing of Rett Gene Therapy

People with Rett syndrome can receive the COVID-19 vaccine from Johnson & Johnson and still participate in future clinical trials of the investigational gene therapy TSHA-102, the treatment’s developer has announced. “We are aware of concerns about the adenovirus vector COVID-19 vaccine from Johnson & Johnson (J&J) and its…

Grant Will Fund Study of Breathing Difficulties

A $2.1 million grant will fund a study investigating if — and how — cells called astrocytes might affect the irregular breathing associated with Rett syndrome. Such disordered breathing is associated with a higher mortality rate and scientists remain unsure of how mutations in the MECP2 gene — the…